Sun et al., 2023 - Google Patents
Discovery of the first potent, selective, and in vivo efficacious polo-like kinase 4 proteolysis targeting chimera degrader for the treatment of TRIM37-amplified breast …Sun et al., 2023
- Document ID
- 6292081971790806401
- Author
- Sun Y
- Xue Y
- Sun P
- Mu S
- Liu H
- Sun Y
- Wang L
- Wang J
- Wu T
- Yin W
- Qin Q
- Sun Y
- Liu N
- Wang H
- Yang H
- Zhao D
- Cheng M
- Publication year
- Publication venue
- Journal of Medicinal Chemistry
External Links
Snippet
Polo-like kinase 4 (PLK4) is a master regulator of centriole replication and has been proposed as a therapeutic target for multiple cancers, especially TRIM37-amplified breast cancer. The development of novel and effective therapeutic strategies for TRIM37-amplified …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kwon et al. | Design, synthesis, and biological activity of sulfonamide analogues of antofine and cryptopleurine as potent and orally active antitumor agents | |
| Engelhardt et al. | Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors | |
| Vaswani et al. | Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl)-2-methyl-1-(1-(1-(2, 2, 2-trifluoroethyl) piperidin-4-yl) ethyl)-1 H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas | |
| Singh et al. | Design of novel 3-pyrimidinylazaindole CDK2/9 inhibitors with potent in vitro and in vivo antitumor efficacy in a triple-negative breast cancer model | |
| Nacht et al. | Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα | |
| Fraser et al. | Rapid discovery and structure–activity relationships of pyrazolopyrimidines that potently suppress breast cancer cell growth via SRC kinase inhibition with exceptional selectivity over ABL kinase | |
| Zhao et al. | Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands | |
| Mao et al. | Potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor developed by structure-based virtual screening and hit optimization | |
| Sun et al. | Discovery of the first potent, selective, and in vivo efficacious polo-like kinase 4 proteolysis targeting chimera degrader for the treatment of TRIM37-amplified breast cancer | |
| Nakano et al. | Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound | |
| Wang et al. | Discovery of first-in-class dual PARP and EZH2 inhibitors for triple-negative breast cancer with wild-type BRCA | |
| Hanafi et al. | Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91 | |
| Nguyen et al. | Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors | |
| Luo et al. | Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation | |
| Chen et al. | Discovery of novel dual histone deacetylase and mammalian target of rapamycin target inhibitors as a promising strategy for cancer therapy | |
| Lafleur et al. | Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography | |
| De Fusco et al. | Fragment-based design of a potent MAT2a inhibitor and in vivo evaluation in an MTAP null xenograft model | |
| McCoull et al. | Optimization of highly kinase selective bis-anilino pyrimidine PAK1 inhibitors | |
| Qin et al. | Development of organometallic S6K1 inhibitors | |
| Khair et al. | Discovery of CDK5 inhibitors through structure-guided approach | |
| Han et al. | Discovery of a selective and potent inhibitor of mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2) utilizing structure-based drug design | |
| Heightman et al. | Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2 | |
| Sun et al. | Discovery of the first lactate dehydrogenase proteolysis targeting chimera degrader for the treatment of pancreatic cancer | |
| Yuan et al. | Discovery of dual CDK6/PIM1 inhibitors with a novel structure, high potency, and favorable druggability for the treatment of acute myeloid leukemia | |
| Davis-Gilbert et al. | Discovery of a Potent and Selective Naphthyridine-Based Chemical Probe for Casein Kinase 2 |